Key Highlights: Implications: Akums’ CDSCO/DCGI approval to manufacture colchicine 0.5 mg for cardiovascular risk reduction is a “first‑time‑in‑India” regulatory milestone that lets India’...
Key Highlights: Implications: Triple Hair is turning TH07 into a genuinely global late‑stage asset in male pattern hair loss by running synchronized Phase III trials in Canada and In...
Key Highlights: Implications: The dispersible format gives Akums a clear differentiation edge in the acute migraine space, directly addressing nausea and swallowing difficulties that often...
